8:15 PM
 | 
Jun 08, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Reltecimod passes futility analysis in Phase III

Atox Bio Inc. (Ness Ziona, Israel) said an IDMC recommended continuation of the Phase III ACCUTE trial of reltecimod (AB103) to treat necrotizing soft tissue infections (NSTIs) in about 290 patients. The prespecified futility analysis evaluated safety and efficacy in the first...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >